

# A SINGLE AMINO ACID SUBSTITUTION IN THE $\alpha 3$ DOMAIN OF AN H-2 CLASS I MOLECULE ABROGATES REACTIVITY WITH CTL

BY TERRY A. POTTER,\* JEFFREY A. BLUESTONE,<sup>§</sup> AND T. V. RAJAN\*<sup>‡</sup>

*From the Departments of \*Pathology, and <sup>‡</sup>Microbiology and Immunology, Albert Einstein College of Medicine, New York 10461; and the <sup>§</sup>Transplantation Biology Section, Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205*

Surface molecules encoded by the MHC provide the context for antigen recognition by T lymphocytes (1). The molecular cloning of the genes, as well as genes for the T cell receptor, has provided a means for studying the relationship between T cell function and the specificity for MHC class I or class II molecules. The molecular mapping of determinants on H-2 class I molecules that are recognized by alloreactive cytotoxic T lymphocytes (CTL) was accomplished by the analysis of hybrid H-2 class I molecules constructed by exon shuffling in vitro. Such studies showed that the reactivity of CTL specific for H-2 class I molecules was directed at determinants in the  $\alpha 1$  and  $\alpha 2$  domains (2–4). A similar finding was obtained with CTL directed against chemically modified H-2 class I molecules, as well as H-2 class I-restricted antiviral CTL responses (5–7).

Previously, we isolated by immunoselection a somatic cell mutant that expressed a D<sup>d</sup> molecule that failed to express a serologic determinant (34.2.12) that had been mapped to the  $\alpha 3$  domain, while retaining all of the serologically defined  $\alpha 1$  and  $\alpha 2$  determinants (8). In contrast to what had been predicted from the exon-shuffling experiments, cells expressing this mutant D<sup>d</sup> molecule were not killed by anti-D<sup>d</sup>-reactive CTL. It remained possible that, in addition to the change in the  $\alpha 3$  domain that resulted in the loss of 34.2.12 binding, there were changes in the  $\alpha 1$  or  $\alpha 2$  domain of the variant H-2D<sup>d</sup> molecule, and that the  $\alpha 1/\alpha 2$  changes were responsible for the loss of CTL reactivity. We have now determined that exon 4 of the mutant D<sup>d</sup> gene has undergone a single mutation resulting in a glutamic acid to lysine substitution at residue 227 in the  $\alpha 3$  domain. Using oligonucleotide-directed mutagenesis, we have reproduced this mutation in the cloned H-2D<sup>d</sup> gene. Cells transfected with this gene are not recognized by alloreactive anti-D<sup>d</sup> CTL. Our studies therefore raise the possibility that, though not identified in the exon-shuffling experiments, residues in the  $\alpha 3$  domain of H-2 class I molecules contribute to determinants recognized by CTL.

---

This work was supported by grants CA-29194, CA-13330, and AI-10702 from the National Institutes of Health; grant PCM 8400114 from the National Science Foundation; and grant CD 293 from the American Cancer Society.

## Materials and Methods

*Mice.* All strains of mice used in this study were either bred in our own colony (NIH, Bethesda, MD) or purchased from The Jackson Laboratory (Bar Harbor, ME).

*Cell Lines.* The D<sup>d</sup> somatic cell variant ACCb 34.2.12<sup>-4</sup> H-2<sup>b-</sup> has been described previously (8). In brief, it was isolated by immunoselection (9) using the anti-D<sup>d</sup> mAb 34.2.12 and rabbit complement, after pretreating the parental cell line ACCb (H-2<sup>d</sup> × H-2<sup>b</sup>)F<sub>1</sub> with the chemical mutagen ethylmethane sulfonate.

The other cell line into which the D<sup>d</sup> genes were transfected, R8.69.9.15 (referred to herein as R8.15), was isolated from R8 (H-2<sup>d</sup> × H-2<sup>b</sup>)F<sub>1</sub> by immunoselection (10). The R8.15 cell line does not possess H-2<sup>d</sup>-encoded genes. The T cell hybridoma, 3DT.52.5.8 was a kind gift from Dr. P. Marrack, and is described elsewhere (11, 12).

*Sequencing of D<sup>d</sup> mRNA from the Parental and Mutant Cell Lines.* The sequence of the α3 domain of the H-2D<sup>d</sup> molecules was determined by sequencing uncloned mRNA using the procedure of Geliebter et al. (13). In brief, RNA was extracted from 2 × 10<sup>9</sup> cells using the guanidinium isothiocyanate method (14) and the poly(A)<sup>+</sup> fraction was isolated by passage through oligo(dT) cellulose (15). An oligonucleotide complementary to and specific for mRNA at residues 287–281 (16) was labelled with <sup>32</sup>P using T4 polynucleotide kinase, and 5 ng was annealed to 10 μg of the poly(A)<sup>+</sup> RNA at 50°C. The primer was extended using avian myeloblastosis virus reverse transcriptase (Life Sciences Inc., St. Petersburg, FL) at 50°C for 45 min. Electrophoresis of the samples was performed in 8% acrylamide sequencing gels.

*Northern Blots.* 30 μg of total RNA was electrophoresed in a 1% agarose gel containing formaldehyde (1%) in borate buffer. The separated RNA was transferred to Gene Screen (New England Nuclear, Boston, MA) paper and hybridized in 5× SSC/10× Denhardt's solution/10% dextran sulfate/7% SDS overnight, at 5°C below the denaturation temperature of the oligonucleotide, as previously described (17). The blots were washed at the hybridizing temperature for 1 h in 3× SSC/10% Denhardt's solution/5% SDS, and then 1 h in 1× SSC/1% SDS.

*Oligonucleotide-directed Mutagenesis of the D<sup>d</sup> Gene.* The D<sup>d</sup> gene, present as an 8 kb Eco RI fragment in pBR327 was kindly provided by Dr. David Margulies (NIH). The 1,996 bp Hpa I fragment containing exons 4–8 of D<sup>d</sup> was ligated to Kpn I linkers (New England Biolabs, Beverly, MA) and cloned into M13mp19. Mutagenesis was performed using the oligonucleotide-directed in vitro mutagenesis system from Amersham Corp. (Arlington Heights, IL). This procedure produces a higher frequency of plaques with the mutant sequence, as it exploits the observation that a strand that incorporates thiolated nucleotides is not nicked by restriction enzymes such as Nci I (18). Thus, after the template strand is nicked with Nci I, it is partially digested with exonuclease III and then resynthesized with DNA polymerase I to form a mutant homoduplex. In separate reactions, two oligonucleotides were used: one with the wild-type sequence and the other the mutant sequence containing the mismatched basepair in the middle. The DNA was transformed into *Escherichia coli* K12 TG1 (TG1) rendered transformation competent with CaCl<sub>2</sub> (19).

Eight plaques arising from the mutagenesis with both the mutant and the wild oligonucleotides were grown up and spotted onto Gene Screen paper and probed with the oligonucleotide used for priming under the same conditions as described above for the Northern blots. In both cases, the priming oligonucleotide hybridized with seven of the eight plaques. Single-stranded phage DNA was prepared, and the sequence was confirmed by DNA sequencing using standard M13 dideoxynucleotide sequencing. Double-stranded DNA from one of these phages was isolated by alkaline lysis from 50 ml of TG1 that had been infected at OD<sub>600</sub> 1.0 with 10<sup>10</sup> PFU/ml of phage and grown for 2 h at 37°C. The 2 kb Kpn I fragment was ligated into the unique Kpn I site in the pSV2-neo plasmid containing the rest of the D<sup>d</sup> gene (see Fig. 3). The correct orientation was identified by restriction mapping with Xmn I.

*Transfection of the Wild Type and Mutant D<sup>d</sup> Genes.* The wild type and mutant D<sup>d</sup> genes that had been cloned into pSV2neo were transfected into R8.15 by electroporation as described by Potter et al. (20) using 10<sup>7</sup> cells and 100 μg of uncut plasmid DNA. 48 h

after electroporation, G-418 sulfate antibiotic (Gibco, Grand Island, NY) was added to a final concentration of 1.0 mg/ml. Clones appeared 14–20 d later and were assayed for expression of H-2D<sup>d</sup> by microcytotoxicity using the  $\alpha 1/\alpha 2$  D<sup>d</sup>-specific mAb 34.4.21.

*Flow Microfluorometric Analysis of H-2 Antigen Expression.* For immunofluorescence staining,  $10^6$  cells in 100  $\mu$ l of DME/FCS were incubated for 30 min on ice with an optimal amount (10  $\mu$ l) of anti-H-2D<sup>d</sup> mAb. The cells were then washed and incubated on ice for a further 30 min with FITC-conjugated goat anti-mouse immunoglobulin. After staining, the cells were washed, and the fluorescence of 20,000 viable cells was measured on a FACS II (Becton Dickinson Immunocytometry Systems, Mountain View, CA).

*Generation of Specific CTL Populations.* Allogeneic effector cells were generated by in a 5-d primary culture of C57BL/10 spleen cells as previously described (21, 22). In brief,  $5 \times 10^6$  splenic responder cells or  $2 \times 10^6$  purified T cells were mixed with  $4 \times 10^6$  irradiated (3,300 rad) stimulator cells in a final volume of 2 ml of culture media. An exogenous source of IL-2 (lectin-free Con A-induced supernatant) was added to some cultures to a final concentration of 10%. The cultures were incubated for 5–6 d at 37°C in 10% CO<sub>2</sub>.

*Measurement of CTL Reactivity by <sup>51</sup>Cr Release.* Target cells were radiolabelled with <sup>51</sup>Cr by incubating  $2-4 \times 10^6$  cells in 300  $\mu$ Ci of Na<sup>51</sup>CrO<sub>3</sub> in 0.3 ml FCS for 1 h. Radiolabelled cells were then washed three times and resuspended at  $5 \times 10^4$  cells/ml. Effector cells were harvested and resuspended at  $5 \times 10^6$  cells/ml. Effector cells and target cells (100  $\mu$ l) were incubated together in 96-well U-bottom plates (Costar, Cambridge, MA) for 4–5 h at 37°C. Culture supernatants were harvested using the Titertek Supernatant Collection System (Skatron Inc., Sterling, VA). Specific lysis was determined as: percent specific release =  $100 \times [(\text{experimental release}) - (\text{spontaneous release})] / [(\text{maximum release}) - (\text{spontaneous release})]$ . The experimental lysis represents the release of <sup>51</sup>Cr from target cells incubated with effector cells. The spontaneous lysis is given by the release of <sup>51</sup>Cr from target cells in the absence of effector cells. The maximum release is given by the release of <sup>51</sup>Cr released by target cells in the presence of 0.05 N HCl.

*Measurement of Stimulation of the IL-2-secreting Hybridoma.* The ability of the transfected cells to stimulate IL-2 production by the T cell hybridoma 3DT.52.5.8 was assayed as described by Greenstein et al., (23). In brief,  $10^5$  3DT.52.5.8 cells were cultured with  $10^5$  irradiated stimulator cells in a total volume of 1 ml for 24 h at 37°C. The supernatant was harvested and aliquots were assayed for their ability to support the growth of the IL-2-dependent cell line CTLL-1, by measuring the incorporation of [<sup>3</sup>H]thymidine during a 6-h pulse with 2  $\mu$ Ci/well [<sup>3</sup>H]thymidine.

## Results

*Identification of the Mutation in the Somatic Cell Variant.* The sequence of the  $\alpha 3$  domain of the D<sup>d</sup> molecule in the ACCb 34.2.12<sup>-4</sup> H-2<sup>b</sup> cell line was determined by sequencing of the H-2D<sup>d</sup> mRNA using an oligonucleotide that hybridized to H-2D<sup>d</sup> mRNA in the transmembrane region. The sequence of the entire  $\alpha 3$  domain was determined and compared with the published nucleotide sequence of H-2D<sup>d</sup> (24), as well as the sequence determined for the  $\alpha 3$  domain of the H-2D<sup>d</sup> molecule of the parental cell line. There was only a single nucleotide difference, a G to A transition near the middle of the domain that resulted in a substitution of lysine in the mutant molecule for the wild-type glutamic acid at residue 227 (Fig. 1). The identification of an acid to base substitution is consistent with the observation that the mutant D<sup>d</sup> molecule has a more basic isoelectric point (8). It is noteworthy that in all the H-2 class I sequences determined, residue 227 is an aspartic acid, whereas it is glutamic acid in H-2D<sup>d</sup>. Therefore, it is most likely that this residue composes part of the determinant recognized by the H-2D<sup>d</sup>-specific mAb 34.2.12.

	<u>224</u>	<u>225</u>	<u>226</u>	<u>227</u>	<u>228</u>	<u>229</u>	<u>230</u>
ACCb H-2 <sup>b-</sup>	CTG	ACC	CAG	GAA	ATG	GAG	CTT
	Leu	Thr	Gln	Glu	Met	Glu	Leu
ACCb 34.2.12 <sup>-4</sup> H-2 <sup>b-</sup>	...	...	...	A...	...	...	...
				Lys			

FIGURE 1. Part of the nucleotide sequence of the wild-type (from ACCb H-2<sup>b-</sup>) and the mutant (from ACCb 34.2.12<sup>-4</sup> H-2<sup>b-</sup>) D<sup>d</sup> gene as determined by RNA sequencing. The sequence of the entire  $\alpha 3$  domain of the D<sup>d</sup> mRNA from both cell lines was determined, and the only difference with that of the published H-2D<sup>d</sup> sequence (24) was at residue 227, as shown.




FIGURE 2. Northern blot of wild-type and mutant D<sup>d</sup> RNA. RNA was isolated from the ACCb H-2<sup>b-</sup> (lanes 1, 3, and 5) and mutant ACCb 34.2.12<sup>-4</sup> H-2<sup>b-</sup> (lanes 2, 4, and 6) cell lines and after electrophoresis and transfer to a Gene Screen filter, probed with oligonucleotides. The sequences of all three oligonucleotides were complementary to that of H-2D<sup>d</sup> mRNA. Lanes 1 and 2, an oligonucleotide to residues 287–281; Lanes 3 and 4, an oligonucleotide to the wild-type D<sup>d</sup> sequence from residues 230–224, and lanes 5 and 6, an oligonucleotide to the mutant D<sup>d</sup> sequence from residues 230–224.

The sequence alteration determined for the mutant D<sup>d</sup> molecule was confirmed by Northern blot analysis using oligonucleotides specific for the parental and mutant sequences. As can be seen in Fig. 2, RNA from both the parental and mutant cell lines hybridized with the oligonucleotide to the H-2D<sup>d</sup> transmembrane region that was used as a primer for the RNA sequencing (Fig. 2, lanes 1 and 2). The oligonucleotide specific for the wild-type H-2D<sup>d</sup> sequence from residues 224–230 hybridized with RNA from the parental cell line but not with RNA from the mutant cell line (Fig. 2, lanes 3 and 4). Similarly, the oligonucleotide specific for the mutant sequence in this region hybridized with RNA from the mutant cell line but not RNA from the parental cell line (Fig. 2, lanes 5 and 6). The results of these Northern blots therefore confirm the existence of the mutation identified in the RNA sequencing of the mutant D<sup>d</sup> molecule.

Having identified the nature of the mutation in ACCb 34.2.12<sup>-4</sup> H-2<sup>b-</sup>, we reproduced this change and examined its effect in the cloned H-2D<sup>d</sup> gene. The H-2D<sup>d</sup> gene cloned in pBR327 was obtained from Dr. D. Margulies, and mutagenesis was performed as described in the Materials and Methods as well as Fig. 3. The cell line R8.15 was chosen as the recipient cell for the reconstructed genes for the following technical reasons: (a) it is readily transfectable by electroporation; (b) it is a good target for measuring specific CTL reactivity and; (c) it does not possess any H-2<sup>d</sup>-encoded genes (10).

Clones that were resistant to G418 were examined for expression of H-2D<sup>d</sup> by




FIGURE 3. Scheme for oligonucleotide-directed mutagenesis of the fourth exon of H-2D<sup>d</sup>. The H-2D<sup>d</sup> gene, cloned as an 8 kb Eco RI fragment in pBR327, was obtained from Dr. David Margulies. Plasmid DNA was cut with Hpa I. Kpn I linkers were ligated and the fragment containing exons 4-8 was cloned into MI3mp19. Oligonucleotide-directed mutagenesis was performed as described in the Materials and Methods. The fragment containing exons 1-3 of D<sup>d</sup> was cloned in pBR327 by the addition of Kpn I linkers at the Hpa I site at the 3' end of the gene and religating with the unique Kpn I site

in the third intron. This 4.2 kb Eco RI fragment was then cloned into the unique Eco RI site of pSV2-neo. To reconstruct the gene after mutagenesis, double-stranded RF DNA containing exons 4-8 was isolated, digested with DNA, and cloned into the unique Kpn I site in the pSV2-neo plasmid containing H-2D<sup>d</sup> exons 1-3. Note that although a 700 bp Kpn I-Hpa I fragment in intron 3 is lost in this manipulation, it was not necessary for expression of H-2D<sup>d</sup>. The black boxes denote the H-2D<sup>d</sup> exons. Restriction enzyme sites: R, Eco RI; K, Kpn I; Hp, Hpa I.

microcytotoxicity. Three cloned cell lines were selected for study: (a) R8.15, the G418-sensitive cell line without any transfected genes; (b) R8.15 D<sup>d</sup> Glu, a G418-resistant clone that was transfected with pSV2-neo containing the H-2D<sup>d</sup> gene with glutamic acid at residue 227 (wild-type D<sup>d</sup>); (c) R8.15 D<sup>d</sup> Lys, a G418-resistant clone that was transfected with pSV2-neo containing the H-2D<sup>d</sup> gene with lysine at residue 227 (mutant D<sup>d</sup>). The expression of the H-2D<sup>d</sup> molecule on these three cell lines was further analyzed by flow microfluorometry on the FACS. As shown in Fig. 4, the anti-D<sup>d</sup> mAbs 34.2.12 and 34.5.8 did not react with R8.15, but did react with R8.15 D<sup>d</sup> Glu. The R8.15 D<sup>d</sup> Lys cell line reacted with the 34.5.8 but not the 34.2.12 antibody and therefore expressed the same serological change as the somatic cell mutant ACCb 34.2.12<sup>-4</sup> H-2<sup>b</sup>.

**Reactivity of Anti-D<sup>d</sup> CTL for the Transfected Cells.** Having established that R8.15 D<sup>d</sup> Lys showed the same loss of a serologic determinant as the original somatic cell variant, we examined whether it would serve as a target for anti-D<sup>d</sup> CTL. As shown in Fig. 5, anti-D<sup>d</sup> CTL generated in a primary in vitro response lysed the R8.15 D<sup>d</sup> Glu but not the R8.15 D<sup>d</sup> Lys cells. This finding suggested that the substitution of Lys at residue 227 of the H-2D<sup>d</sup> molecule in R8.15 D<sup>d</sup> Lys reproduced not only the change in serologic determinants, but also the failure of recognition by anti-D<sup>d</sup>-reactive T cells.

**Stimulation of IL-2 Production in 3DT.52.5.8 by the Transfected Cells.** The T cell hybridoma 3DT.52.5.8 secretes IL-2 when stimulated by a target cell expressing H-2D<sup>d</sup>. The ability of the three cell lines to elicit IL-2 secretion in 3DT.52.5.8 was determined. It was found that both R8.15 D<sup>d</sup> Glu as well as R8.15 D<sup>d</sup> Lys stimulated production of IL-2 by 3DT.52.5.8 (Table I). Therefore, although R8.15 D<sup>d</sup> Lys is not lysed by anti-D<sup>d</sup> CTLs, the mutant D<sup>d</sup> molecule still stimulates an anti-H-2D<sup>d</sup>-specific, IL-2-producing T cell hybridoma.




FIGURE 4. Reactivity of anti-D<sup>d</sup> antibodies 34.5.8 and 34.2.12 with R8.15, and the transfectants R8.15 D<sup>d</sup> Glu and R8.15 D<sup>d</sup> Lys, detected on the FACS.




FIGURE 5. Reactivity of anti-D<sup>d</sup> CTL with R8.15 and the D<sup>d</sup> transfectants. The target cell lines were R8.15 (Δ); R8.15 D<sup>d</sup> Glu (●); and R8.15 D<sup>d</sup> Lys (□). The effector cells were C57BL/6 α B10.YBR (A) and C57BL/6 α B10.A (5R) (B). Values are given as percent specific release.

### Discussion

Site-directed mutagenesis and exon shuffling have proved to be useful approaches to the study of structure-function relationships of H-2 class I molecules (2-7, 25, 26). The difficulty in using site-directed mutagenesis to define structure-function relationships for molecules such as H-2 class I that have as many as 270 extracellular amino acids is deciding what residues to alter and what

TABLE I  
*Stimulation of IL-2 Production by 3DT.52.5.8 in Response to the Transfected Cell Lines*

Cell line	[ <sup>3</sup> H]Thymidine uptake (cpm)*
R8.15	830 ± 96
R8.15 D <sup>d</sup> Glu	10,997 ± 402
R8.15 D <sup>d</sup> Lys	9,986 ± 752

\* Results are expressed as the mean ± SD of six replicate cultures measuring [<sup>3</sup>H]thymidine incorporation into the IL-2-dependent cell line CTLL-1.

residues should be introduced. Exon-shuffling experiments (2–7) have established that allele-specific determinants recognized by alloreactive CTL reside in the  $\alpha 1$  and  $\alpha 2$  domains. In contrast, recent studies on the recognition of a hybrid MHC class I molecule between the mouse H-2K<sup>b</sup> and the human HLA-A2 genes have demonstrated that replacement of the H-2K<sup>b</sup>  $\alpha 3$  domain with that of the HLA-A2 gene can abrogate recognition by some anti-H-2K<sup>b</sup> CTL (27 and Marziarz and Bluestone, manuscript in preparation). This observation raises the possibility that the  $\alpha 3$  domain may be involved in CTL recognition. Our approach to the identification of informative structural changes has been to perform immunoselections with mAbs and characterize the functional and structural changes. We have been particularly interested in the  $\alpha 3$  domain and have isolated somatic cell mutants with structural changes in the  $\alpha 3$  domain of the H-2L<sup>d</sup> (28) or H-2D<sup>d</sup> (8) molecule. We found that, for the H-2L<sup>d</sup> mutants, there was no detectable effect on T cell reactivity. In contrast, a somatic cell mutant isolated by immunoselection using an mAb to the H-2D<sup>d</sup>  $\alpha 3$  domain was no longer recognized by anti-D<sup>d</sup>-reactive CTL (8).

In this paper we have sequenced mRNA encoding the mutant D<sup>d</sup> molecule and identified a glutamic acid to lysine change at position 227 in the  $\alpha 3$  domain. We have reproduced this mutation in vitro by oligonucleotide-directed mutagenesis of a cloned H-2D<sup>d</sup> gene and transfected the mutant gene into a H-2D<sup>d-</sup> cell line. Cells transfected with this mutant gene have the same characteristics as the original H-2D<sup>d</sup> somatic cell mutant. Cells transfected with this gene do not express the 34.2.12 determinant nor are they recognized by alloreactive D<sup>d</sup> CTL. As the effector CTL cells used were bulk populations generated in primary in vitro responses and not single cloned lines, they most probably represented a polyclonal response, with specificity for several H-2D<sup>d</sup> allele-specific determinants.

A trivial explanation for this apparent abrogation of CTL recognition by the change at residue 227 is that the change in charge destroys the conformation of the D<sup>d</sup> molecule. Arguments against this explanation are: (a) the reactivity of the mutant D<sup>d</sup> molecule with  $\alpha 1/\alpha 2$  antibodies such as 34.5.8 (Fig. 4) 34.4.21, 34.4.20, 15.1.5, 20.8.6 (data not shown) is indistinguishable from the wild-type D<sup>d</sup> molecule; (b) the mutant molecule is associated with  $\beta_2$  microglobulin (data not shown); (c) the mutant molecule stimulates the 3DT.52.5.8 hybridoma to secrete IL-2. It should also be noted that between the allelic variations of the  $\alpha 3$  domains used in the exon-shuffling experiments there are between four to six

differences that involved changes in charged residues, and these apparently have no effect on recognition by CTL.

Our data would at first seem to be in conflict with the exon-shuffling experiments, which suggested that residues in the  $\alpha 3$  domain are not recognized by CTL. It is possible to reconcile our findings with those of the exon-shuffling experiments by proposing that the  $\alpha 3$  domain expresses a conserved or monomorphic determinant(s) recognized by CTL, and that this determinant is destroyed by the glutamic acid to lysine substitution at residue 227. If such a putative monomorphic or invariant determinant does exist, then replacement of the  $\alpha 3$  domain with the  $\alpha 3$  domain of other H-2 class I genes or alleles in the exon-shuffling experiments would not have revealed its presence. Of the three external domains, the most likely one to express a conserved determinant would be the  $\alpha 3$  domain, since this region has the greatest level of amino acid homology among different H-2 class I genes and alleles. In particular, residues 200–250 are identical in the H-2K<sup>k</sup>, D<sup>b</sup>, and L<sup>d</sup> genes, H-2K<sup>b</sup> shows one substitution, and H-2K<sup>d</sup> and H-2D<sup>d</sup> each have only two substitutions (24, 29–33). There exists much greater allelic variation in the  $\alpha 1$  and  $\alpha 2$  domains. It may therefore be that selective pressure has not only generated variation in the  $\alpha 1/\alpha 2$  domains, but also conserved an invariant  $\alpha 3$  domain.

Evidence for the existence of conserved determinants on MHC class I and class II molecules has come from blocking experiments using mAbs (34, 35). These experiments suggest that molecules such as Lyt-2 (for class I) and L3T4 (for class II) molecules (36) provide accessory recognition to that of the T cell receptor. This is particularly evident in clones with lower affinity (37). Furthermore, Dembic et al. (38) have recently demonstrated that transfection of the CD8/Lyt-2 gene enhances cytotoxicity by T cells given the T cell receptor  $\alpha$  and  $\beta$  chain genes from a donor CTL line.

Our results establish that residue 227 contributes to a determinant recognized by most CTL but not by the IL-2-producing hybridoma 3DT.52.5.8. The 3DT.52.5.8 hybridoma is L3T4<sup>-</sup> and Lyt-2<sup>-</sup> (23), indicating that these molecules are not involved in the recognition of D<sup>d</sup> by the hybridoma. The fact that H-2D<sup>d</sup> stimulates IL-2 secretion in 3DT.52.5.8, even in the absence of accessory molecules, suggests that the antigen-specific receptor on 3DT.52.5.8 is of high affinity. We therefore propose that the anti-D<sup>d</sup> CTL populations that we assayed need to recognize a conserved determinant in the  $\alpha 3$  domain as well as the allele-specific determinants in  $\alpha 1/\alpha 2$ . In contrast, the 3DT.52.5.8 hybridoma needs to recognize only the  $\alpha 1/\alpha 2$  allele-specific determinants and not the conserved determinant in  $\alpha 3$ . The noninvolvement of the conserved determinant in recognition by 3DT.52.5.8 may be due either to the hybridoma expressing a receptor of very high affinity for the  $\alpha 1/\alpha 2$  determinants, or alternatively, that the threshold for IL-2 stimulation may be lower than that required for CTL lysis. We are currently extending these studies by generating CTL that have high affinity for their target cell and are not dependent on accessory molecules, such as Lyt-2, for reactivity. If such high-affinity CTL need only to recognize  $\alpha 1/\alpha 2$  determinants and not the conserved determinant in  $\alpha 3$ , we predict that such CTL should be able to lyse cells such as R8.15 D<sup>d</sup> Lys, in which the conserved determinant has been destroyed.



### Summary

We previously described a somatic cell expressing a variant H-2D<sup>d</sup> molecule that did not serve as a target for alloreactive anti-D<sup>d</sup> CTL. The mutant cell line had been isolated by its failure to express a serological epitope present on the H-2D<sup>d</sup>  $\alpha 3$  domain. In the present study the  $\alpha 3$  domain of the D<sup>d</sup> molecule of this somatic cell variant was sequenced and a single nucleotide change resulting in a glutamic acid to lysine substitution at residue 227 was identified. This change was reproduced in the cloned H-2D<sup>d</sup> gene by oligonucleotide-directed mutagenesis. Cells transfected with this mutant gene were not killed by anti-H-2D<sup>d</sup> CTL. Because previous studies using hybrid H-2 class I molecules had established that the  $\alpha 3$  domain does not express allele-specific determinants recognized by CTL, our results raise the possibility that residues in the  $\alpha 3$  domain of H-2 class I molecules are critical for CTL recognition and constitute a conserved (or monomorphic) determinant recognized by CTL.

We are most grateful to Dr. D. Margulies for providing the cloned H-2D<sup>d</sup> gene and to Dr. P. Marrack for the 3DT.52.5.8 hybridoma cell line. We thank Dr. Nadine Chien for help with the RNA sequencing technique, Mrs. Edith Palmieri for synthesizing oligonucleotides, and Mrs. Kathy Rapelje and Michele Foo for expert technical assistance with the FACS and CTL analysis, respectively. We wish to also thank Ms. Rosina Passela for the preparation of this manuscript.

*Received for publication 29 June 1987.*

### References

1. Klein, J., F. Figueroa, and Z. Nagy. 1983. Genetics of the major histocompatibility complex: The final act. *Annu. Rev. Immunol.* 1:119.
2. Evans, G. A., D. H. Margulies, B. Shykind, J. G. Seidman, and K. Ozato. 1983. Exon shuffling: Mapping polymorphic determinants on hybrid mouse transplantation antigens. *Nature (Lond.)*. 300:755.
3. Ozato, K., G. A. Evans, B. Shykind, D. H. Margulies, and J. G. Seidman. 1983. Hybrid H-2 histocompatibility gene products assign domains recognized by alloreactive T cells. *Proc. Natl. Acad. Sci. USA*. 80:2040.
4. Allen, H., D. Wraith, P. Pala, B. Askonas, and R. A. Flavell. 1984. Domain interactions of H-2 class I antigens alter cytotoxic T-cell recognition sites. *Nature (Lond.)*. 309:279.
5. Reiss, C. S., G. A. Evans, D. H. Margulies, J. G. Seidman, and S. J. Burakoff. 1983. Allospecific and virus-specific cytolytic T lymphocytes are restricted to the N or C1 domain of H-2 antigens expressed on L cells after DNA-mediated gene transfer. *Proc. Natl. Acad. Sci. USA*. 80:2709.
6. Arnold, B., H. G. Burgert, U. Hamann, G. Hammerling, U. Kees, and S. Kvist. 1984. Cytolytic T cells recognize the two amino-terminal domains of H-2K antigens in tandem in influenza A infected cells. *Cell*. 38:79.
7. Levy, R. B., J. C. Richardson, D. H. Margulies, G. A. Evans, J. G. Seidman, and K. Ozato. 1983. The products of transferred H-2 genes express determinants that restrict hapten-specific cytotoxic T cells. *J. Immunol.* 130:2514.
8. Potter, T. A., M. A. Palladino, D. B. Wilson, and T. V. Rajan. 1983. Epitopes on H-2D<sup>d</sup> somatic cell mutants recognized by cytotoxic T cells. *J. Exp. Med.* 158:1061.
9. Rajan, T. V., and E. D. Halay. 1981. Anti-H-2 hybridoma antibodies as immunose-

- lective agents. I. Isolation of forward and reverse mutations for reactivity with a monoclonal antibody. *Immunogenetics*. 14:253.
10. Zeff, R. A., J. Gopas, E. Steinhauer, T. V. Rajan, and S. G. Nathenson. 1986. Analysis of somatic cell H-2 variants to define the structural requirements for class I antigen expression. *J. Immunol.* 137:897.
  11. Marrack, P., R. Enders, R. Shimonkevitz, A. Zlotnik, D. Dialynas, F. Fitch, and J. Kappler. 1985. The major histocompatibility complex-restricted antigen receptor on T cells. II. Role of the L3T4 product. *J. Exp. Med.* 158:1077.
  12. Enders, R., P. Marrack, and J. W. Kappler. 1983. An IL-2-secreting T cell hybridoma that responds to a self class I histocompatibility antigen in the H-2D region. *J. Immunol.* 131:1656.
  13. Geliebter, J., R. A. Zeff, D. H. Schuze, L. R. Pease, E. H. Weiss, A. L. Mellor, R. A. Flavell, and S. G. Nathenson. 1986. Interaction between K<sup>b</sup> and Q4 gene segments generates the K<sup>bm6</sup> mutant. *Mol. Cell. Biol.* 6:645.
  14. Chirgwin, J. M., A. E. Przybyla, R. J. MacDonald, and W. J. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. *Biochemistry*. 18:5294.
  15. Aviv, H., and P. Leder. 1972. Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. *Proc. Natl. Acad. Sci. USA*. 69:1408.
  16. Kress, M., W.-Y. Liu, E. Jay, G. Khoury, and G. Jay. 1983. Comparison of class I (H-2) gene sequences: Derivation of unique probes for members of this multigene family. *J. Biol. Chem.* 258:13929.
  17. Potter, T. A., R. A. Zeff, A. M. Schmitt-Verhulst, and T. V. Rajan. 1985. Molecular analysis of an EL4 cell line that expresses H-2D<sup>b</sup> but not H-2K<sup>b</sup> or  $\beta$ 2-microglobulin. *Proc. Natl. Acad. Sci. USA*. 82:2950.
  18. Taylor, J. W., J. Ott, and F. Eckstein. 1985. The rapid generation of oligonucleotide-directed mutations a high frequency using phosphorothioate-modified DNA. *Nucleic Acids Res.* 13:8764.
  19. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. *Molecular Cloning. A Laboratory Manual*. Cold Spring Harbor Laboratory, NY.
  20. Potter, H., L. Weir, and P. Leder. 1984. Enhancer-dependent expression of human K immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. *Proc. Natl. Acad. Sci. USA*. 81:7161.
  21. Levy, R. B., K. Ozato, J. C. Richman, and J. A. Bluestone. 1985. Molecular localization of allogeneic and self determinants recognized by bulk and cloned populations of cytotoxic T cells. *J. Immunol.* 134:1342.
  22. McCluskey, J., L. Boyd, M. Foo, J. Forman, D. H. Margulies, and J. A. Bluestone. 1986. Analysis of hybrid H-2D and L antigens with reciprocally mismatched amino-terminal domains: Functional T cell recognition requires preservation of fine structural determinants. *J. Immunol.* 137:3881.
  23. Greenstein, J. L., B. Malissen, and S. J. Burakoff. 1985. Role of L3T4 in antigen-driven activation of a class I-specific T cell hybridoma. *J. Exp. Med.* 162:369.
  24. Sher, B. T., R. Nairn, J. E. Coligan, and L. E. Hood. 1985. DNA sequence of the mouse H-2D<sup>d</sup> transplantation antigen gene. *Proc. Natl. Acad. Sci. USA*. 82:1175.
  25. Shiroishi, T., G. A. Evans, E. Appella, and K. Ozato. 1985. In vitro mutagenesis of a mouse MHC class I gene for the examination of structure-function relationships. *J. Immunol.* 134:623.
  26. Miyazaki, J. E., E. Appella, H. Zhao, J. Forman, and K. Ozato. 1986. Expression and function of a nonglycosylated major histocompatibility class I antigen. *J. Exp. Med.* 163:856.

27. Bluestone, J. A. 1987. Analysis of structure-function relationships among MHC class I antigens. *Immunol. Res.* 6:67.
28. Bluestone, J. A., T. A. Potter, S. Chattersee-Hasrouni, and T. V. Rajan. 1984. CTL recognize different determinants from those defined serologically on L<sup>d</sup> somatic cell mutants. *J. Immunol.* 133:1168.
29. Arnold, B., H.-G. Burgert, A. L. Archibald, and S. Kvist. 1984. Complete nucleotide sequence of the murine H-2K<sup>k</sup> gene: Comparison of three H-2K locus alleles. *Nucleic Acids Res.* 12:9473.
30. Weiss, E., L. Golden, R. Zakut, A. Mellor, K. Fahrner, S. Kvist, and R. A. Flavell. 1983. The DNA sequence of the H-2K<sup>b</sup> gene: Evidence for gene conversion as a mechanism for the generation of polymorphism in histocompatibility antigens. *EMBO (Eur. Mol. Biol. Organ.) J.* 2:453.
31. Reyes, A. A., M. Schold, and R. B. Wallace. 1982. The complete amino acid sequence of the murine transplantation antigen H-2D<sup>b</sup> as deduced by molecular cloning. *Immunogenetics.* 16:1.
32. Kvist, S., L. Roberts, and B. Dobberstein. 1983. Mouse histocompatibility genes: Structure and organization of a K<sup>d</sup> gene. *EMBO (Eur. Mol. Biol. Organ.) J.* 2:245.
33. Evans, G. A., D. H. Margulies, R. D. Camerini-Otero, K. Ozato, and J. G. Seidman. 1982. Structure and expression of a mouse major histocompatibility antigen gene H-2L<sup>d</sup>. *Proc. Natl. Acad. Sci. USA.* 79:1994.
34. Swain, S. L. 1981. Significance of Lyt phenotypes: Lyt-2 antibodies block activities of T cells that recognize class I major histocompatibility complex antigens regardless of their function. *Proc. Natl. Acad. Sci. USA.* 78:7101.
35. Swain, S. L. 1983. T cell subsets and the recognition of MHC class. *Immunol. Rev.* 74:129.
36. Dialynas, D. P., D. B. Wilde, P. Marrack, A. Pierres, K. A. Wall, W. Havran, G. Otten, M. R. Loken, M. Pierres, J. Kappler, and F. W. Fitch. 1983. Characterization of the murine antigenic determinant designated L3T4a, recognized by monoclonal antibody GK1.5; expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. *Immunol. Rev.* 74:19.
37. MacDonald, H. R., A. L. Glasebrook, C. Bron, A. Kelso, and J. C. Cerottini. 1982. Clonal heterogeneity in the functional requirement for Lyt-2,3 molecules on cytotoxic T lymphocytes (CTL): possible implications for the affinity of CTL antigen receptors. *Immunol. Rev.* 68:69.
38. Dembic, Z., W. Haas, R. Zamoyska, J. Parnes, M. Steinmetz, and H. vonBoehmer. 1987. Transfection of the CD8 gene enhances T cell recognition. *Nature (Lond.)* 326:510.